Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.85
- Piotroski Score 1.00
- Grade Buy
- Symbol (CTXR)
- Company Citius Pharmaceuticals, Inc.
- Price $0.22
- Changes Percentage (11.35%)
- Change $0.02
- Day Low $0.20
- Day High $0.24
- Year High $1.07
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/27/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.23
- Trailing P/E Ratio -2.65
- Forward P/E Ratio -2.65
- P/E Growth -2.65
- Net Income $-32,542,912
Income Statement
Quarterly
Annual
Latest News of CTXR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Turn A Profit?
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company aiming for profitability soon. Analysts project it to break even in 2025 with a 63% annual growth rate. The absence of debt reduc...
By Yahoo! Finance | 3 months ago -
Citius Pharmaceuticals, Inc. (CTXR) Stock Price, News, Quote & History
Citius Pharmaceuticals is a biopharmaceutical company focusing on critical care products. They have two late-stage product candidates, Mino-Lok and LYMPHIR, with ongoing clinical trials. The company i...
By Yahoo! Finance | 4 months ago
